Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
The closing price of AnaptysBio Inc (NASDAQ: ANAB) was $45.21 for the day, up 2.96% from the previous closing price of $43.91. In other words, the price has increased by $2.96 from its previous closing price. On the day, 0.67 million shares were traded. ANAB stock price reached its highest trading level at $47.36 during the session, while it also had its lowest trading level at $43.59.
Ratios:
Our analysis of ANAB’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 8.68 and its Current Ratio is at 8.68.
On October 13, 2025, Barclays started tracking the stock assigning a Overweight rating and target price of $78.
H.C. Wainwright Upgraded its Neutral to Buy on June 04, 2025, while the target price for the stock was maintained at $38.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jan 07 ’26 when ERIC J LOUMEAU bought 7,622 shares for $45.69 per share.
Faga Daniel sold 15,309 shares of ANAB for $662,267 on Jan 05 ’26. The President, CEO now owns 458,139 shares after completing the transaction at $43.26 per share. On Jan 05 ’26, another insider, Daniel Faga, who serves as the Officer of the company, bought 15,309 shares for $44.95 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ANAB now has a Market Capitalization of 1264659200 and an Enterprise Value of 1349289728. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.39. Its current Enterprise Value per Revenue stands at 7.962 whereas that against EBITDA is -48.014.
Stock Price History:
The Beta on a monthly basis for ANAB is 0.36, which has changed by 2.0900774 over the last 52 weeks, in comparison to a change of 0.19182634 over the same period for the S&P500. Over the past 52 weeks, ANAB has reached a high of $52.47, while it has fallen to a 52-week low of $12.21. The 50-Day Moving Average of the stock is 8.52%, while the 200-Day Moving Average is calculated to be 62.91%.
Shares Statistics:
ANAB traded an average of 507.64K shares per day over the past three months and 421680 shares per day over the past ten days. A total of 27.58M shares are outstanding, with a floating share count of 25.90M. Insiders hold about 6.48% of the company’s shares, while institutions hold 112.60% stake in the company. Shares short for ANAB as of 1765756800 were 5644248 with a Short Ratio of 11.12, compared to 1763078400 on 5930320. Therefore, it implies a Short% of Shares Outstanding of 5644248 and a Short% of Float of 38.689997999999996.
Earnings Estimates
As of right now, 9.0 analysts gave their recommendation on the stock of the company. The consensus estimate for the next quarter is -$1.1, with high estimates of -$0.51 and low estimates of -$1.78.
Analysts are recommending an EPS of between -$0.49 and -$3.66 for the fiscal current year, implying an average EPS of -$1.4. EPS for the following year is -$4.1, with 9.0 analysts recommending between $1.1 and -$7.83.
Revenue Estimates
It is expected that $90B in revenue will be generated in . The current quarter, according to 11 analysts. It ranges from a high estimate of $104.3M to a low estimate of $36M. As of . The current estimate, AnaptysBio Inc’s year-ago sales were $43.11M
A total of 11 analysts have provided revenue estimates for ANAB’s current fiscal year. The highest revenue estimate was $230.6M, while the lowest revenue estimate was $148M, resulting in an average revenue estimate of $205.31M. In the same quarter a year ago, actual revenue was $91.28M
